Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Over the past years, the impact of varenicline in patients with mental illness has been debated as serious neuropsychiatric adverse events (AEs) have been reported with varenicline use. AIM: To identify and summarize published case reports of neuropsychiatric AEs ascribed to varenicline and to determine potential risk factors for these AEs. METHODS: A literature search of MEDLINE, the Cochrane Library, EMBASE, and PsychInfo database was conducted for case reports concerning the neuropsychiatric AEs of varenicline published in English from 2006 (approval year by the US Food and Drug Administration and the Dutch Medicines Evaluation Board) to January 1, 2012. RESULTS: We identified 25 published cases. In most reports, patients had been admitted to psychiatric hospitals with serious neuropsychiatric AEs due to varenicline. The average patient age was 46.4 years, and 56% were men; 68% of patients had a psychiatric history. The onset of symptoms started 2 days to 3 months after the initiation of varenicline. One report described completed suicide in a man with no psychiatric history. In most cases (84%), the neuropsychiatric symptoms resolved after the discontinuation of varenicline. Analysis of all reports using the Naranjo causality scale, a method for estimating the probability of adverse drug reactions, indicated probable causality in 76% of the cases and definite causality in 12% of cases. CONCLUSION: Varenicline is associated with an increased risk of serious neuropsychiatric AEs, especially in patients with a psychiatric illness. It is strongly recommended that varenicline be administered only to mentally stable patients and under close monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ahmed et al.40 analyzed 25 published case reports spanning from 2006, when varenicline received FDA approval, to 2012. Analysis of all reports using the Naranjo causality scale, a method for estimating the probability of adverse drug reactions, indicated probable causality in 76% of the cases and definite causality in 12% of the cases.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [40]
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 1×
“Most smokers who try to quit smoking on their own relapse within the first week of quitting.(6,7) However, success rates can be improved if people are assisted in their attempt to quit smoking, and especially if pharmacological treatment is combined with behavioral counseling.”
BackgroundVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Benowitz, N. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.3 · Cited by 517 · cited 1×
“Nicotine stimulates the release of multiple neurotransmitters, including dopamine, serotonin, norepinephrine, acetylcholine, glutamate, endorphins, and gamma-aminobutyric acid.(63) Through direct activation of nicotinic acetylcholine receptors, specifically >4A2 receptors, varenicline stimulates the release of dopamin…”
BackgroundHyland, A., Borland, R., Li, Q., Yong, H.-H., McNeill, A., Fong, G. T., O’Connor, R. J., & Cummings, K. M. (2006) · Tobacco Control · doi:10.1136/tc.2005.013516 · Cited by 507
Neurobiological mechanisms in major depressive disorder
aan het Rot, M., Mathew, S. J., & Charney, D. S. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080697 · Cited by 470
Aubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344
The role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291 · cited 1×
“There is considerable evidence that dopamine and serotonin play a crucial role in the pathophysiology of various psychiatric illnesses, such as depression,(64) schizophrenia,(65) and bipolar disorder.(66) Whereas the baseline activity of dopamine and serotonin in the brain is stable in smokers with or without mental i…”
BackgroundComorbidity between patterns of substance use dependence and psychiatric syndromes
Kandel, D. B., Huang, F.-Y., & Davies, M. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00126-0 · Cited by 221 · cited 2×
“However, approximately 27% of the general population has or has had mental illness,(25) and the prevalence of tobacco use and nicotine dependence is significantly higher among individuals with a psychiatric disorder.(26) Approximately 41% of current smokers report having being diagnosed with a mental illness or a subs…”
BackgroundStapleton, J. A., Watson, L., Spirling, L. I., Smith, R., Milbrandt, A., Ratcliffe, M., & Sutherland, G. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02083.x · Cited by 208 · cited 1×
“A retrospective study from the UK (n = 208) showed that the presence of mental illness (n = 53 of 208) did not influence the development and/or exacerbation of neuropsychiatric adverse events in patients who used varenicline.(34) In a study based on the UK General Practice Research Database, Gunnell et al.”
BackgroundGunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200 · cited 2×
“In a study based on the UK General Practice Research Database, Gunnell et al.(36) reported a hazard ratio for self-harm among individuals prescribed varenicline of 1.”
BackgroundInfluentialde Vries, H., Candel, M., Engels, R., & Mercken, L. (2006) · Tobacco Control · doi:10.1136/tc.2003.007237 · Cited by 192
Exacerbation of Schizophrenia by Varenicline
Freedman, R. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07020326 · Cited by 191
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Aveyard, P., & West, R. (2007) · BMJ · doi:10.1136/bmj.39252.591806.47 · Cited by 150
Tsai, S.-T., Cho, H., Cheng, H., Kim, C.-H., Hsueh, K.-C., Billing, C. B., & Williams, K. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.011 · Cited by 139
Varenicline-Induced Manic Episode in a Patient With Bipolar Disorder
Kohen, I., & Kremen, N. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010173 · Cited by 126
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004010037 · Cited by 108
McClure, J. B., Swan, G. E., Jack, L., Catz, S. L., Zbikowski, S. M., McAfee, T. A., Deprey, M., Richards, J., & Javitz, H. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0926-8 · Cited by 93 · cited 2×
“In a larger study (n = 1117), McClure et al.(32) did not find that smokers with a history of depression were more likely to experience new or significantly worse mood disturbance than were smokers without depression.”
BackgroundHoogendoorn, M., Welsing, P. M. J., & Mölken, M. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x242917 · Cited by 77 · cited 2×
“A cohort study investigating the cost-effectiveness of varenicline compared with currently available pharmacological alternatives in Dutch smokers found varenicline to be costeffective compared with nortriptyline and unaided cessation and even cost-saving compared with bupropion and NRT.22 The results of similar cost-…”
ResultWorsening Psychosis Induced by Varenicline in a Hospitalized Psychiatric Patient
DiPaula, B. A., & Thomas, M. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.852 · Cited by 56
Varenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression
Pumariega, A. J., Nelson, R., & Rotenberg, L. (2008) · CNS Spectrums · doi:10.1017/s1092852900016746 · Cited by 55
Varenicline Treatment for Smokers With Schizophrenia: A Case Series
Evins, A. E., & Goff, D. C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0620a · Cited by 50
Exacerbation of Recurrent Depression as a Result of Treatment With Varenicline
Popkin, M. K. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111735 · Cited by 50
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46
Varenicline: The newest agent for smoking cessation
Potts, L. A., & Garwood, C. L. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060428 · Cited by 40
Varenicline Withdrawal-Induced Delirium With Psychosis
MAY, A. C., & Rose, D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081194 · Cited by 38 · cited 1×
“Interestingly, in 2 reports, the neuropsychiatric symptoms occurred after the discontinuation of varenicline.(51,53) In 40% of the cases, mania was the major neuropsychiatric symptom; other symptoms were psychosis, 36% (including hallucinations and delirium); suicidal ideation, 28% (including completed suicide); depre…”
BackgroundFagerström, K., Nakamura, M., Cho, H.-J., Tsai, S.-T., Wang, C., Davies, S., Ma, W., Lee, T. C., & Russ, C. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.505130 · Cited by 34 · cited 1×
“Participants were randomly assigned to receive varenicline (1 mg twice daily) or placebo.(21) The abstinence rate was higher with varenicline than with placebo during weeks 9 to 12 (58.”
MethodVarenicline-Induced Mania in a Bipolar Patient
Alhatem, F. J., & Black, J. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31816f75bc · Cited by 32
Risk of psychiatric side effects with varenicline
Moore, T. J., & Furberg, C. D. (2009) · BMJ · doi:10.1136/bmj.b4964 · Cited by 24
Lyon, G. J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818db354 · Cited by 24
Pirmoradi, P., Roshan, S., & Nadeem, S. S. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070641 · Cited by 21
Varenicline-induced Mixed Mood and Psychotic Episode in a Patient with Schizoaffective Disorder
Liu, M., Tsai, S., & Yang, S.-T. (2009) · CNS Spectrums · doi:10.1017/s1092852900022975 · Cited by 21
Visual hallucinations associated with varenicline: a case report
Raidoo, B. M., & Kutscher, E. C. (2009) · Journal of Medical Case Reports · doi:10.1186/1752-1947-3-7560 · Cited by 17
Chantix-induced mental status changes in a young healthy female.
Kutscher, E. C., Stanley, M. D., & Oehlke, K. (2009) · PubMed · Cited by 15
Hallucinations in the Context of Varenicline Withdrawal
LAINE, P., MARTTILA, J., & Lindeman, S. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091370 · Cited by 13 · cited 1×
“Interestingly, in 2 reports, the neuropsychiatric symptoms occurred after the discontinuation of varenicline.(51,53) In 40% of the cases, mania was the major neuropsychiatric symptom; other symptoms were psychosis, 36% (including hallucinations and delirium); suicidal ideation, 28% (including completed suicide); depre…”
BackgroundA case of late-life onset mania during Varenicline assisted smoking cessation
Francois, D., Odom, A. E., & Kotbi, N. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2615 · Cited by 10
Júnior, A. R. T., & Volpe, F. M. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000300017 · Cited by 5
Forcén, F. E., Martinez, F., & Moya, A. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.7 · Cited by 4
Late-onset Wilson's disease presenting with general anxiety disorder
Habek, M., Gabelić, T., Brinar, V. V., & Pavliša, G. (2009) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2009.00408.x · Cited by 3
Bancila, V., Dallon, C., & ZULLINO, D. F. (2009) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2009.00417.x · Cited by 3
Baran, X. Y., & Docherty, J. P. (2010) · CNS Spectrums · doi:10.1017/s1092852900027401 · Cited by 3 · cited 2×
“In 2 cases, varenicline was not discontinued.(54,56) In the first case, the neuropsychiatric symptoms resolved within 4 weeks of the initiation of bupropion (150 mg/d)(54); and in the second case, the symptoms resolved the day that single-dose sertraline (25 mg) was started.”
Background
Cited by
Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 180
Re-evaluating the link between neuropsychiatric disorders and dysregulated adult neurogenesis
Yun, S., Reynolds, R. P., Masiulis, I., & Eisch, A. J. (2016) · Nature Medicine · doi:10.1038/nm.4218 · Cited by 128
Cancer screening, prevention, and treatment in people with mental illness
Weinstein, L. C., Stefančić, A., Cunningham, A., Hurley, K. E., Cabassa, L. J., & Wender, R. C. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21334 · Cited by 119
“”(73) In contrast, another study assessed neuropsychiatric adverse events associated with varenicline and, using a method for estimating the probability of adverse drug reactions, concluded that varenicline was responsible for probable causality in 76% of cases and definite causality in 12% of cases.(69) Although that…”
ResultEjiofor, S., & Turner, A. M. (2013) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s7211 · Cited by 57
Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S. (2015) · BMJ · doi:10.1136/bmj.h2388 · Cited by 54
Metadata
- Authors
- Ahmed, A. I. A., Ali, A. N. A., Kramers, C., Härmark, L. V. D., Burger, D. M., & Verhoeven, W. M. A.
- Affiliations
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- University of Groningen (NL)
- Corresponding author
- Ahmed, Amir I.A.
- Verhoeven, Willem M.A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2013-02
- Volume
- 33
- Issue
- 1
- Pages
- 55-62
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2045752876
- Cited by
- 34
- References
- 49
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 3
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- varenicline, neuropsychiatric adverse effects, smoking cessation, nicotine receptor partial agonist, suicide, psychiatric comorbidity, risk factors, drug discontinuation
- MeSH terms
- Varenicline, Smoking Prevention, Adult, Aged, Mental Disorders, Benzazepines, Female, Humans, Male, Middle Aged, Quinoxalines, Risk Factors, Time Factors, Comorbidity, Smoking Cessation, Risk Assessment, Nicotinic Agonists, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.